Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
Korean J Intern Med. 2019 Nov;34(6):1188-1196. doi: 10.3904/kjim.2019.071. Epub 2019 Jul 29.
The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations.
结直肠癌（CRC）的发病率正在上升。CRC 是韩国第三大常见癌症和第四大癌症相关死亡原因。当无法治愈时，姑息性化疗可用于缩小肿瘤并缓解癌症引起的症状。确定可有效治疗转移性 CRC（mCRC）的化疗药物，从而改善 mCRC 患者的生存和生活质量非常重要。本综述旨在评估 mCRC 姑息化疗的最新进展以及基于遗传改变使用的生物或靶向药物。
